{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:40:08Z","timestamp":1769236808722,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1208\/aapsj070115","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T16:16:44Z","timestamp":1126628204000},"page":"E143-E148","source":"Crossref","is-referenced-by-count":36,"title":["Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials"],"prefix":"10.1208","volume":"7","author":[{"given":"Summer","family":"Burstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"71143_CR1","first-page":"381","volume-title":"Cannabis and Cannabinoids","author":"S Burstein","year":"2002","unstructured":"Burstein S. Therapeutic Potential of Ajulemic Acid (CT-3): In: Grontenhermen F, Russo E, eds.Cannabis and Cannabinoids. Binghamton, NY: Haworth Press Inc; 2002;381\u2013388."},{"key":"71143_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2174\/1381612003399473","volume":"6","author":"SH Burstein","year":"2000","unstructured":"Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.Curr Pharm Des. 2000;6:1339\u20131345.","journal-title":"Curr Pharm Des."},{"key":"71143_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0163-7258(98)00069-2","volume":"82","author":"SH Burstein","year":"1999","unstructured":"Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.Pharmacol Ther. 1999;82:87\u201396.","journal-title":"Pharmacol Ther."},{"key":"71143_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.lfs.2004.04.010","volume":"75","author":"SH Burstein","year":"2004","unstructured":"Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a \u201chigh\u201d.Life Sci. 2004;75:1513\u20131522.","journal-title":"Life Sci."},{"key":"71143_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF01940427","volume":"43","author":"S Burstein","year":"1987","unstructured":"Burstein S, Hunter SA, Latham V, Renzulli L. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.Experientia. 1987;43:402\u2013403.","journal-title":"Experientia."},{"key":"71143_CR6","first-page":"94","volume":"9","author":"S Burstein","year":"1981","unstructured":"Burstein S, Shoupe TS. Metabolic pathways for the transformation of delta 1-tetrahydrocannabinol in mouse hepatic microsomes.Drug Metab Dispos. 1981;9:94\u201396.","journal-title":"Drug Metab Dispos."},{"key":"71143_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1126\/science.176.4033.422","volume":"176","author":"S Burstein","year":"1972","unstructured":"Burstein S, Rosenfeld J, Wittstruck T. Isolation and characterization of two major urinary metabolites of 1-tetrahydrocannabinol.Science. 1972;176:422\u2013423.","journal-title":"Science."},{"key":"71143_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0009-2797(71)90078-0","volume":"3","author":"SH Burstein","year":"1971","unstructured":"Burstein SH, Kupfer D. Hydroxylation of trans-1-tetrahydrocannabinol by a hepatic microsomal monooxygenase.Chem Biol Interact. 1971;3:316.","journal-title":"Chem Biol Interact."},{"key":"71143_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/225087a0","volume":"225","author":"SH Burstein","year":"1970","unstructured":"Burstein SH, Menezes F, Williamson E, Mechoulam R. Metabolism of delta 1(6)-tetrahydro-cannabinol, an active marihuana constituent.Nature, 1970;225:87\u201388.","journal-title":"Nature"},{"key":"71143_CR10","first-page":"287","volume-title":"Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs","author":"M Perez-Reyes","year":"1985","unstructured":"Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, eds.Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publishers; 1985;287\u2013310."},{"key":"71143_CR11","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/0006-2952(86)90053-5","volume":"35","author":"S Burstein","year":"1986","unstructured":"Burstein S, Hunter SA, Latham V, Renzulli L. Prostaglandins and cannabis-XVI. Antagonism of delta 1-tetrahydrocannabinol action by its metabolites.Biochem Pharmacol. 1986;35:2553\u20132558.","journal-title":"Biochem Pharmacol."},{"key":"71143_CR12","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1096\/fasebj.2.14.2846397","volume":"2","author":"SH Burstein","year":"1988","unstructured":"Burstein SH, Hull K, Hunter SA, Latham V. Cannabinoids and pain responses: a possible role for prostaglandins.FASEB J. 1988;2:3022\u20133026.","journal-title":"FASEB J."},{"key":"71143_CR13","first-page":"531","volume":"251","author":"SH Burstein","year":"1989","unstructured":"Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V. Antagonism to the actions of platelet activating factor by a non-psychoactive cannabinoid.J Pharmacol Exp Ther. 1989;251:531\u2013535.","journal-title":"J Pharmacol Exp Ther."},{"key":"71143_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF02003237","volume":"31","author":"SA Doyle","year":"1990","unstructured":"Doyle SA, Burstein SH, Dewey WL, Welch SP. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid.Agents Actions. 1990;31:157\u2013163.","journal-title":"Agents Actions."},{"key":"71143_CR15","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1021\/jm00095a007","volume":"35","author":"SH Burstein","year":"1992","unstructured":"Burstein SH, Audette CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.J Med Chem. 1992;35: 3135\u20133141.","journal-title":"J Med Chem."},{"key":"71143_CR16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jama.290.13.1757","volume":"290","author":"M Karst","year":"2003","unstructured":"Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.JAMA. 2003;290: 1757\u20131762.","journal-title":"JAMA."},{"key":"71143_CR17","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/jm970126f","volume":"40","author":"MH Rhee","year":"1997","unstructured":"Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.J Med Chem. 1997;40:3228\u20133233.","journal-title":"J Med Chem."},{"key":"71143_CR18","first-page":"218","volume":"265","author":"DR Compton","year":"1993","unstructured":"Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.J Pharmacol Exp Ther. 1993;265:218\u2013226.","journal-title":"J Pharmacol Exp Ther."},{"key":"71143_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0006-2952(01)00700-6","volume":"62","author":"LD Recht","year":"2001","unstructured":"Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.Biochem Pharmacol. 2001;62:755\u2013763.","journal-title":"Biochem Pharmacol."},{"key":"71143_CR20","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0024-3205(97)00122-7","volume":"60","author":"SA Hunter","year":"1997","unstructured":"Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis.Life Sci. 1997;60:1563\u20131573.","journal-title":"Life Sci."},{"key":"71143_CR21","unstructured":"Stebulis JA, Burstein SH, Torres R, et al. Ajulemic Acid, an antiinflammatory nonpsychoactive cannabinoid acid, modulates activation of human synovial cells. Paper presented at: 2004 Symposium on the Cannabinoids. June 20, 2004; Paestum, Italy."},{"key":"71143_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","volume":"41","author":"RB Zurier","year":"1998","unstructured":"Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11-oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure.Arthritis Rheum. 1998;41:163\u2013170.","journal-title":"Arthritis Rheum."},{"key":"71143_CR23","first-page":"31","volume":"291","author":"EZ Dajani","year":"1999","unstructured":"Dajani EZ, Larsen KR, Taylor J, et al. 1\u2032,1\u2032-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.J Pharmacol Exp Ther. 1999;291:31\u201338.","journal-title":"J Pharmacol Exp Ther."},{"key":"71143_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0024-3205(98)00256-2","volume":"63","author":"SH Burstein","year":"1998","unstructured":"Burstein SH, Friderichs E, Kogel B, Schneider J, Selve N. Analgesic effects of 1\u2032,1\u2032 dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice.Life Sci. 1998;63:161\u2013168.","journal-title":"Life Sci."},{"key":"71143_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1521-6616(03)00064-0","volume":"108","author":"B Bidinger","year":"2003","unstructured":"Bidinger B, Torres R, Rossetti RG, et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes.Clin Immunol. 2003;108:95\u2013102.","journal-title":"Clin Immunol."},{"key":"71143_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1124\/mol.63.5.983","volume":"63","author":"J Liu","year":"2003","unstructured":"Liu J, Li, H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.Mol Pharmacol. 2003;63:983\u2013992.","journal-title":"Mol Pharmacol."},{"key":"71143_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","volume":"65","author":"RB Zurier","year":"2003","unstructured":"Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1 beta production by ajulemic acid, a nonpsychoactive cannabinoid.Biochem Pharmacol. 2003;65:649\u2013655.","journal-title":"Biochem Pharmacol."},{"key":"71143_CR28","unstructured":"Walker JM, Owen K, Petros P, Huang SM. Antiallodynic and analgesic actions of ajulemic acid reversed by a cannabinoid antagonist. Paper presented at: Society of Neuroscientists; November 9, 2000; New Orleans, LA."},{"key":"71143_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/art.20050","volume":"50","author":"PF Sumariwalla","year":"2004","unstructured":"Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.Arthritis Rheum. 2004;50:985\u2013998.","journal-title":"Arthritis Rheum."},{"key":"71143_CR30","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.20805","volume":"50","author":"SH Burstein","year":"2004","unstructured":"Burstein SH, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al.Arthritis Rheum. 2004;50:4078\u20134080.","journal-title":"Arthritis Rheum."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/aapsj070115\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:41:50Z","timestamp":1559619710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/aapsj070115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["71143"],"URL":"https:\/\/doi.org\/10.1208\/aapsj070115","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}